Embrace New Findings to Enhance Practice

Recent reviews highlight two critical developments that should guide current practice. First, recent EASIS trials reveal that anticoagulants do not offer a significant advantage over antiglipid agents in randomized controlled trials. Secondly, the long-awaited publication of two trials concerning subclinical atrial fibrillation (AFib), identified through devices like implantable loop recorders, has emerged after four to five years of research. Understanding these findings, especially regarding the implications of subclinical AFib, is essential for evolving treatment approaches.